chr7-30609704-C-G

Position:

• chr7-30609704-C-G

Variant summary

Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_Moderate BS2

The NM_002047.4(GARS1):​c.855C>G​(p.Phe285Leu) variant causes a missense change. The variant allele was found at a frequency of 0.0000109 in 1,461,344 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).

• Frequency:
  • Genomes: not found (cov: 33)
  • Exomes 𝑓: 0.000011 (0 hom.)
• Consequence: GARS1 NM_002047.4 missense
• Clinical Significance: Uncertain significance criteria provided, multiple submitters, no conflicts U:2
• Conservation: PhyloP100: 4.09

Genes affected

GARS1 (HGNC:4162): (glycyl-tRNA synthetase 1) This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]

GARS1 (HGNC:):

ACMG classification

Verdict is Likely_benign. Variant got -6 ACMG points.

• BP4: Computational evidence support a benign effect (MetaRNN=0.14031723).
• BS2: High AC in GnomAdExome4 at 16 AD gene.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	Protein	UniProt
GARS1	NM_002047.4	c.855C>G	p.Phe285Leu	missense_variant	7/17	ENST00000389266.8	NP_002038.2
GARS1	NM_001316772.1	c.693C>G	p.Phe231Leu	missense_variant	7/17		NP_001303701.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Protein	Appris	UniProt
GARS1	ENST00000389266.8	c.855C>G	p.Phe285Leu	missense_variant	7/17	1	NM_002047.4	ENSP00000373918.3
GARS1	ENST00000675651.1	c.855C>G	p.Phe285Leu	missense_variant	7/17			ENSP00000502513.1
GARS1	ENST00000675810.1	c.753C>G	p.Phe251Leu	missense_variant	6/16			ENSP00000502743.1
GARS1	ENST00000675693.1	c.687C>G	p.Phe229Leu	missense_variant	8/18			ENSP00000502174.1
GARS1	ENST00000675051.1	c.654C>G	p.Phe218Leu	missense_variant	7/17			ENSP00000502296.1
GARS1	ENST00000674815.1	c.486C>G	p.Phe162Leu	missense_variant	7/17			ENSP00000502799.1
GARS1	ENST00000674851.1	c.486C>G	p.Phe162Leu	missense_variant	8/18			ENSP00000502451.1
GARS1	ENST00000444666.6	n.855C>G		non_coding_transcript_exon_variant	7/18	3		ENSP00000415447.2
GARS1	ENST00000674616.1	n.*569C>G		non_coding_transcript_exon_variant	8/18			ENSP00000502408.1
GARS1	ENST00000674643.1	n.855C>G		non_coding_transcript_exon_variant	7/17			ENSP00000501636.1
GARS1	ENST00000674737.1	n.*193C>G		non_coding_transcript_exon_variant	8/18			ENSP00000502464.1
GARS1	ENST00000674807.1	n.855C>G		non_coding_transcript_exon_variant	7/16			ENSP00000502814.1
GARS1	ENST00000675529.1	n.*725C>G		non_coding_transcript_exon_variant	8/18			ENSP00000501655.1
GARS1	ENST00000675859.1	n.855C>G		non_coding_transcript_exon_variant	7/15			ENSP00000502033.1
GARS1	ENST00000676088.1	n.*797C>G		non_coding_transcript_exon_variant	9/19			ENSP00000501884.1
GARS1	ENST00000676140.1	n.855C>G		non_coding_transcript_exon_variant	7/17			ENSP00000502571.1
GARS1	ENST00000676164.1	n.*306C>G		non_coding_transcript_exon_variant	7/17			ENSP00000501986.1
GARS1	ENST00000676210.1	n.*144C>G		non_coding_transcript_exon_variant	8/18			ENSP00000502373.1
GARS1	ENST00000676259.1	n.*287C>G		non_coding_transcript_exon_variant	7/17			ENSP00000501980.1
GARS1	ENST00000676403.1	n.855C>G		non_coding_transcript_exon_variant	7/16			ENSP00000502681.1
GARS1	ENST00000674616.1	n.*569C>G		3_prime_UTR_variant	8/18			ENSP00000502408.1
GARS1	ENST00000674737.1	n.*193C>G		3_prime_UTR_variant	8/18			ENSP00000502464.1
GARS1	ENST00000675529.1	n.*725C>G		3_prime_UTR_variant	8/18			ENSP00000501655.1
GARS1	ENST00000676088.1	n.*797C>G		3_prime_UTR_variant	9/19			ENSP00000501884.1
GARS1	ENST00000676164.1	n.*306C>G		3_prime_UTR_variant	7/17			ENSP00000501986.1
GARS1	ENST00000676210.1	n.*144C>G		3_prime_UTR_variant	8/18			ENSP00000502373.1
GARS1	ENST00000676259.1	n.*287C>G		3_prime_UTR_variant	7/17			ENSP00000501980.1

Frequencies

GnomAD3 genomes Cov.: 33

GnomAD3 exomes AF: 0.00000802 AC: 2 AN: 249406 Hom.: 0 AF XY: 0.0000148 AC XY: 2 AN XY: 135320

Gnomad AFR exome AF: 0.00

Gnomad AMR exome AF: 0.00

Gnomad ASJ exome AF: 0.00

Gnomad EAS exome AF: 0.00

Gnomad SAS exome AF: 0.00

Gnomad FIN exome AF: 0.00

Gnomad NFE exome AF: 0.0000177

Gnomad OTH exome AF: 0.00

GnomAD4 exome AF: 0.0000109 AC: 16 AN: 1461344 Hom.: 0 Cov.: 30 AF XY: 0.0000110 AC XY: 8 AN XY: 726986

Gnomad4 AFR exome AF: 0.00

Gnomad4 AMR exome AF: 0.00

Gnomad4 ASJ exome AF: 0.00

Gnomad4 EAS exome AF: 0.00

Gnomad4 SAS exome AF: 0.00

Gnomad4 FIN exome AF: 0.00

Gnomad4 NFE exome AF: 0.0000126

Gnomad4 OTH exome AF: 0.0000331

GnomAD4 genome Cov.: 33

Bravo AF: 0.00000378

ClinVar

Significance: Uncertain significance

Submissions summary: Uncertain:2

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

not specified Uncertain:1

Uncertain significance, criteria provided, single submitter

clinical testing

Ambry Genetics

Dec 18, 2020

The p.F285L variant (also known as c.855C>G), located in coding exon 7 of the GARS gene, results from a C to G substitution at nucleotide position 855. The phenylalanine at codon 285 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -

Charcot-Marie-Tooth disease type 2 Uncertain:1

Uncertain significance, criteria provided, single submitter

clinical testing

Labcorp Genetics (formerly Invitae), Labcorp

Jul 08, 2017

In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with GARS-related disease. ClinVar contains an entry for this variant (Variation ID: 188141). This variant is not present in population databases (ExAC no frequency). This sequence change replaces phenylalanine with leucine at codon 285 of the GARS protein (p.Phe285Leu). The phenylalanine residue is weakly conserved and there is a small physicochemical difference between phenylalanine and leucine. -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
AlphaMissense	Uncertain	0.37
BayesDel_addAF	Benign	-0.021	T
BayesDel_noAF	Benign	-0.25
CADD	Benign	21
DANN	Benign	0.96
DEOGEN2	Benign	0.13	T
Eigen	Benign	-0.070
Eigen_PC	Benign	0.14
FATHMM_MKL	Pathogenic	0.98	D
LIST_S2	Uncertain	0.96	D
M_CAP	Benign	0.014	T
MetaRNN	Benign	0.14	T
MetaSVM	Benign	-0.77	T
PrimateAI	Uncertain	0.71	T
PROVEAN	Benign	-0.30	N
REVEL	Benign	0.25
Sift	Benign	0.66	T
Sift4G	Benign	0.13	T
Polyphen		0.0010	B
Vest4		0.26
MutPred		0.30		Loss of helix (P = 0.0558);
MVP		0.45
MPC		0.44
ClinPred		0.67	D
GERP RS		5.5
RBP_binding_hub_radar		0.0
RBP_regulation_power_radar		1.8
Varity_R		0.18
gMVP		0.57

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs786204099; hg19: chr7-30649320;